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Abstract
Question
Do prophylactic anticonvulsants decrease the risk of sei-
zure in patients with metastatic brain tumors compared
with no treatment?
Target population
These recommendations apply to adults with solid brain
metastases who have not experienced a seizure due to their
metastatic brain disease.
Recommendation
Level 3 For adults with brain metastases who have
not experienced a seizure due to their metastatic brain dis-
ease, routine prophylactic use of anticonvulsants is not
recommended.
Only a single underpowered randomized controlled trial
(RCT), which did not detect a difference in seizure occur-
rence, provides evidence for decision-making purposes.
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Rationale
Brain metastases are a common complication of systemic
cancer, occurring in approximately 20–40% of patients.
Since an intracranial mass lesion may predispose patients to
seizure,thequestionhasarisenastowhetherprophylacticuse
of anticonvulsants may prevent seizures in this population.
Previously published guidelines on this topic have included
patientswithbothprimaryandsecondarybraintumors[1,2].
The objective of this guideline paper is to speciﬁcally
address the role of anticonvulsant prophylaxis in adults
with solid metastases to the brain. The rationale for this is
that intracranial metastases from systemic cancer tend to be
spherical and more contained when compared to primary
brain tumors which are more inﬁltrative in nature. Given
this difference in typical growth patterns, it is conven-
tionally thought that brain metastases may be less likely to
induce seizures than primary tumors.
Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, Cochrane Database of Abstracts of
Reviews of Effects. A broad search strategy using a com-
bination of subheadings and text words was employed. The
search strategy is documented in the methodology paper
for this guideline series by Robinson et al. [3] Reference
lists of included studies were also reviewed.
Eligibility criteria
For inclusion in this systematic review the following cri-
teria needed to be met:
• Published in English with a publication date of 1990
forward.
• Patients with brain metastases.
• Fully-published peer-reviewed primary comparative
studies (all comparative study designs for primary data
collection included; e.g., RCT, non-randomized trials,
cohort studies or case–control studies).
• Study comparisons include the following:
– anticonvulsant prophylaxis vs. none
• Number of study participants with brain metasta-
ses C 5 per study arm for at least two of the study arms.
• Baseline information on study participants is provided
by treatment group in studies evaluating interventions
exclusively in patients with brain metastases. For
studies with mixed populations (i.e., includes partici-
pants with conditions other than brain metastases),
baseline information is provided for the intervention
sub-groups of participants with brain metastases.
Study selection and quality assessment
Two independent reviewers evaluated citations using a pri-
ori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
secondreviewer.The PEDroscale [4,5] was used torate the
quality of randomized trials. The quality of comparative
studies using non-randomized designs was evaluated using
eight items selected and modiﬁed from existing scales.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper for this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
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123methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
The literature search resulted in the identiﬁcation of 16,966
citations of which 16,962 were eliminated at abstract
review as not having relevance to the speciﬁc question. The
remaining four studies were subject to full text screening,
three of which were excluded because they lacked baseline
patient data for brain metastases sub-group. Only one study
[6] met the eligibility criteria and forms the basis of this
report (see Fig. 1).
Clearly, the role of anticonvulsant use speciﬁcally in the
management of brain metastases has been explored in a
very limited number of controlled comparative trials, and
therefore the class of evidence and hence the recommen-
dations have limited applicability. Table 1 summarizes the
only applicable study, in terms of class of evidence.
This study, by Forsyth et al. [6], is an RCT of anti-
convulsants versus no anticonvulsants in 100 patients with
newly diagnosed brain tumors (diagnosis \1 month from
study entry). Patients were stratiﬁed for primary (n = 40)
or metastatic (n = 60) pathology. Additional eligibility
criteria were adequate hepatic, bone marrow and renal
function. Excluded were patients with limited life expec-
tancy (\4 weeks), known prior seizures, anticonvulsant
allergy, substance abuse and pregnancy. Of patients with
brain metastasis, 26 were treated with anticonvulsants,
usually phenytoin (n = 25) or phenobarbital (n = 1) using
oral loading and conventional maintenance dosing; 34
patients received no anticonvulsants. The primary outcome
reported was seizure occurrence at 3 months post-
randomization.
The trial was terminated early because the seizure rate in
the no anticonvulsant arm was only 10%, which put the
anticipated seizure rate of 20% outside the 95% conﬁdence
interval. In addition, mortality prior to the 3-month follow-
up was much higher than anticipated (observed 30% vs.
projected 15%). The authors of the trial noted that the
combination of these two factors indicated that the power
to detect a clinically important difference in seizure
occurrence between the two groups would be less than 20%
based on the planned-for accrual of 300 patients.
The only outcome reported speciﬁcally for the sub-
group of patients with brain metastases was seizure inci-
dence, and there was no signiﬁcant difference between
those who received anticonvulsant prophylaxis and those
who did not (log rank test; P = 0.90).
Conclusions and discussion
It is very difﬁcult to make recommendations regarding the
role of anticonvulsant prophylaxis in patients with brain
metastases based on sub-group data from one underpow-
ered randomized trial. All of the studies evaluating pro-
phylactic anticonvulsant use identiﬁed by this systematic
review included patients with both primary and secondary
tumors. Only one of these trials stratiﬁed by metastases
versus primary pathology and presented baseline data for
the brain metastases sub-group and, therefore, met the
eligibility criteria for this systematic review.
Given the premise that brain metastases are probably less
likely than primary brain tumors to cause seizures, it is
noteworthy that previously published guidelines on the role
Title and Abstract Screening 
n=16,966 
Full Text Screening 
n=4 
Excluded at Title and 
Abstract 
n=16,962 
Eligible Studies: 1 Included 
Anticonvulsants vs. no anticonvulsants ……1 
3 Excluded 
No data by brain metastases sub-group……3 
Fig. 1 Flow of studies to ﬁnal
number of eligible studies
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123of anticonvulsants in patients with brain tumors (either
primary or secondary) have recommended against their
prophylactic use [1, 2]. Although only the single afore-
mentioned study met our search criteria, the rationale for
making a Level 3 recommendation not to use routine pro-
phylactic anticonvulsants is further explained by the fact
that anticonvulsant use can have signiﬁcant adverse effects,
and by the lack of evidence suggesting any beneﬁt from the
prophylactic use of anticonvulsants for patients with brain
metastases. The key conclusion from these guidelines, then,
is that there is a lack of a clear and robust beneﬁt from the
routine prophylactic use of anticonvulsants.
Key issues for future investigation
Given the ubiquity of anticonvulsant use for prophylactic
and active treatment of seizures associated with metastatic
brain disease, the medical literature contains relatively few
detailed reports speciﬁcally addressing their use. Future
studies could be planned to allow better control, recording
and analysis of anticonvulsant dosing and response to
allow a more robust analysis of the risk to beneﬁt ratio of
various agents. A host of newer anticonvulsants are now
available and in widespread use [7]. These often have a
better safety proﬁle than older agents and lower likelihood
for signiﬁcant drug interactions. Although patients with
metastatic carcinoma may be prone to seizure, prophy-
lactic anticonvulsant use is not recommended. Once a
seizure has occurred, however, anticonvulsants are safe
and effective, especially the newer agents. Unresolved
questions which could be the subject of prospective studies
include the prognosis for patients with a single peri-oper-
ative seizure versus multiple symptomatic seizures, with
regards to long-term control, adverse effects of therapy and
safety.
No ongoing or recently closed clinical trials on the
prophylactic use of anticonvulsants for the manage-
ment of brain metastases were found that met the
eligibility criteria.
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123the individualized care and treatment advice from a patient’s physi-
cian(s). If medical advice or assistance is required, the services of a
competent physician should be sought. The proposals contained in
these guidelines may not be suitable for use in all circumstances. The
choice to implement any particular recommendation contained in
these guidelines must be made by a managing physician in light of the
situation in each particular patient and on the basis of existing
resources.
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